Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29150056 | 0.82 | IDO1 (0.59) | IDO1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL29924668 | 0.82 | IDO1 (0.59) | IDO1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL732698 | 0.79 | SLC6A3 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL13043598 | 0.78 | IDO1 (0.54) | IDO1ALDH1A1MAPTHPGD | |
| SCHEMBL15248884 | 0.78 | IDO1 (0.54) | IDO1ALDH1A1MAPTHPGD | |
| SCHEMBL17456173 | 0.77 | IDO1 (1.00) | IDO1 | |
| SCHEMBL17456174 | 0.77 | IDO1 (1.00) | IDO1 | |
| SCHEMBL15669125 | 0.77 | SLC6A3 (0.52) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL30879548 | 0.76 | SLC9A1 (0.62) | IDO1ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL30879550 | 0.76 | SLC9A1 (0.62) | IDO1ALDH1A1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666473-B1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-8138335-B2 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20100029631-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20090312558-A1 | PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPOANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-12-17 | — | — | US | disclosed |
| WO-2009150660-A1 | A PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-12-17 | — | — | WO | disclosed |
| US-7601712-B2 | Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070004716-A1 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| CN-1882554-A | Carboxylic acid compounds and pharmaceutical compositions containing them as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2006-12-20 | — | — | CN | disclosed |
| EP-1666473-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312558-A1 | PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPOANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | NOTUM, SULT2A1, SULT1A1 | IDO1 1907/4885SLC6A4 3174/4885SLC6A3 2406/4885 |
| US-20100029631-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | GPR17, CYSLTR1, KIT | IDO1 612/4885SLC6A4 3533/4885SLC6A3 3143/4885 |
| US-20070004716-A1 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | GPR17, CYSLTR1, KIT | IDO1 612/4885SLC6A4 3533/4885SLC6A3 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.